Eleva GmbH
June 16, 2025
Company Presentation
Other
Eleva is a clinical-stage biopharmaceutical company that strives to bring novel therapies to patients in need. Partnerships are at the heart of our strategy. Our unique moss-based platform and capabilities can unlock a range of 1st- and best-in-class biologics.
We are currently advancing two proprietary clinical programs, which have the potential to change the life of patients affected from complement-related disorders conditions (e.g. C3G, dry AMD) and Fabry disease.
Eleva is currently looking for additional investors and partners interested to accelerate Eleva's the development of these clinical assets towards the market approval.
Moreover, Eleva scouts for promising novel compounds that will benefit from Eleva’s technology and expertise. We are evaluating alliances to initiate partnered discovery and development projects.
Company HQ City:
Freiburg
Company HQ State:
Baden Wuerttemberg
Company HQ Country:
Germany
Year Founded:
1999
Lead Product in Development:
Factor H
CEO
Dr. Bjoern Cochlovius
Development Phase of Lead Product
Phase I
Number of Unlicensed Products Looking for Licensing
2
When you expect your next catalyst update?
aGal: outlicensing (Phase 1 finalized);
Factor H: Phase 1 finalized Q2 2026
What is your next catalyst (value inflection) update?
aGal: outlicensing (Phase 1 finalized) outlicensing by Q4 2025
Factor H: Phase 1 finalized Q2 2026
Primary Speaker
)
)
)
)
){kind=logo}
){kind=logo}
)
){kind=logo}
)
){kind=logo}